Bronchiolitis Obliterans Syndrome Market ANALYSE DE LA TAILLE ET DU PARTAGE - TENDANCES DE CROISSANCE ET PRÉVISIONS (2024 - 2031)
Bronchiolitis Obliterans Syndrome Market is segmented By Therapy (Budesonide/Formoterol, Montelukast, N-acetylcysteine), By Drug Class (Macrolide Antibiotics, Corticosteroids, Immunosuppressive Drugs), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD Million) for the above-mentioned segments.
Bronchiolitis Obliterans Syndrome Market Size
Taille du Marché en USD Mn
TCAC4.1%
| Période d'Étude | 2024 - 2031 |
| Année de Base de l'Estimation | 2023 |
| TCAC | 4.1% |
| Concentration du Marché | Medium |
| Principaux Acteurs | Zambon Pharma, Incyte Corporation, Genentech, GlaxoSmithKline, Altavant Sciences and Among Others. |
please let us know !
Bronchiolitis Obliterans Syndrome Market Analysis
The bronchiolitis obliterans syndrome market is estimated to be valued at USD 60.37 Mn in 2024 and is expected to reach USD 79.93 Mn by 2031, growing at a compound annual growth rate (CAGR) of 4.1% from 2024 to 2031. The prevalence of bronchiolitis obliterans syndrome (BOS) is increasing which is driving the demand for effective therapeutics. With no approved drug therapy currently available for BOS, the pipeline drugs in late-stage clinical trials holds significant potential to capture market share if approved.